Tuba YILDIRIM, Murat HÖKELEK, Melek BİLGİN

In vitro effects of ıvermectin and sulphadiazine on toxoplasma gondii

Objective: Ivermectin and sulphadiazine were tested individually to determine their in vitro effects on Toxoplasma gondii grown in human epidermoid larynx carcinoma (Hep-2) cell culture. Study Design: In-vitro study. Material and Methods: Toxoplasma growth was quantities by an enzyme immunoassay performed directly on the fixed cultures, using a rabbit anti-T. gondii immunoglobulin G as the first antibody and a phosphatase-labeled anti-rabbit immunoglobulin G as the second antibody. For each drug, regres- sion models were used to quantify the relationship between optical density values and antimicrobial agent concentrations in the cultures. Results: The 50% inhibitory concentrations (IC50) of ivermectin and sulphadiazine were found to be 0.2 μg/mL and 7.3 μg/mL after 48 h of exposure, respectively. None of the concentrations tested for each drugs demonstrated toxicity to Hep-2 cells after 72 h of incubation. Conclusion: These results indicate that ivermectin significantly inhibited replication of the tachyzoites of T. gondii RH strain.

PDF

___

1.Montaya JG, Liesenfeld O.Toxoplasmosis. The Lancet 2004;363:1965-76. [CrossRef]
2.Montoya JG, Kovacs JA, Remington JS. Toxoplasma gondii. In:Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennetts Principles and Practice of Infectious Diseases. 6th ed. Philadelphia:Elsevier Press;2008. p.3170-92.
3.Wilson M, Jones LJ, McAuley LB. Toxoplasma. In:Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clini- cal Microbiology. 9th ed. Washington:ASM Press;2005. p.2070-81.
4.Petersen E. Toxoplasmosis. Seminars in Fetal & Neonatal Medi- cine 2007;12:214-23. [CrossRef]
5.Merli A, Canessa A, Melioli G. Enzyme immunoassay for evalua- tion of Toxoplasma gondii growth in tissue culture. J Clin Micro- biol 1985;21:88-91.
6.Derouin F, Chastang C. Enzyme Immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue cultures. An- timicrob Agents Chemother 1988;32:303-7. [CrossRef]
7.Diab MR, El-Bahy MM. Toxoplasma gondii:Virulence of tachyzo- ites in serum free media at different temperatures. Exp Parasitol 2008;118:75-9. [CrossRef]
8.Meneceuri P, Bouldouyre MA, Aubert D, Villena I, Menotti J, Sau- vage V, et al. Toxoplasma gondii:In vitro susceptibility of various ge- notypic strains to pyrimethamine, sulphadiazine and atovaquone. Antimicrob Agents Chemother 2008;52:1269-77. [CrossRef]
9.Derouin F, Chastang C. In vitro effects of folate inhibitors on Toxo- plasma gondii. Antimicrob Agents Chemother 1989;33:1753-9. [CrossRef]
10.Guzzo CA, Furtek CI, Chen C, Tipping R, Clineschmidt CM, Sci- berras DG, et al. Safety, tolerability, pharmacokinetics of esca- lating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002;42:1122-33. [CrossRef]